GlassScriptPhysician profile
Brandon Brousse
NPI 1508229618
$15,912.79
in general payments reported to CMS, 2019-2025
40 companies · $4,813 in 2025
The $4,813 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $461 · 2021: $795 · 2022: $1,436 · 2023: $3,561 · 2024: $4,223 · 2025: $4,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,355.18 |
| Education | $242.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,511.27 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,358.56 | 2022-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,179.01 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $1,140.83 | 2019-2025 | Vemlidy, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,006.48 | 2021-2025 | Xifaxan, Relistor |
| Celgene Corporation | $833.61 | 2022-2024 | Zeposia |
| Pfizer INC. | $771.84 | 2019-2025 | |
| Genzyme Corporation | $672.00 | 2022-2025 | |
| Ardelyx, INC. | $512.00 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $503.48 | 2022-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $313.20 | 2024-2025 | Iqirvo |
| Boston Scientific Corporation | $300.22 | 2019-2022 | |
| Lilly USA, LLC | $290.87 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $269.87 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $269.35 | 2023-2025 | Ocaliva |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $232.33 | 2023-2025 | Dupixent |
| Conmed Corporation | $210.53 | 2021 | |
| Celltrion USA INC. | $207.97 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $199.67 | 2023-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $174.68 | 2025 | Zenpep, Vowst |
| Ironwood Pharmaceuticals, INC | $174.55 | 2022-2025 | Linzess |
| Madrigal Pharmaceuticals | $174.14 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $153.16 | 2022 | |
| Nestle Healthcare Nutrition INC. | $148.23 | 2021-2023 | |
| Covidien LP | $141.09 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.07 | 2019-2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $121.70 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $108.21 | 2022-2025 | Sutab, Suflave |
| Organon LLC | $108.03 | 2023-2025 | Hadlima |
| Medtronic, INC. | $90.96 | 2021-2023 | Bravo |
| Ferring Pharmaceuticals INC. | $86.22 | 2022-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $83.28 | 2021-2024 | Dificid |
| Micro-Tech Endoscopy USA, INC. | $76.43 | 2024-2025 | Lockado |
| Intra-Sana Laboratories | $71.08 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Redhill Biopharma INC. | $54.06 | 2023 | Movantik, Aemcolo, Talicia |
| Novo Nordisk INC | $36.73 | 2025 | Wegovy |
| Exact Sciences Corporation | $34.71 | 2025 | Cologuard Collection Kit |
| Biocon Biologics INC | $32.89 | 2024-2025 | Yesintek, Hulio |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Brousse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.